REPH - Recro Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.24
+0.06 (+0.84%)
At close: 4:00PM EDT

7.24 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close7.18
Open7.15
Bid5.43 x 1800
Ask7.34 x 1300
Day's Range6.95 - 7.25
52 Week Range4.78 - 13.05
Volume158,182
Avg. Volume188,413
Market Cap149.999M
Beta (3Y Monthly)-0.14
PE Ratio (TTM)N/A
EPS (TTM)-3.00
Earnings DateNov 8, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.30
Trade prices are not sourced from all markets
  • FDA Sets Action Date for Recro's Pain Management Candidate
    Zacks8 days ago

    FDA Sets Action Date for Recro's Pain Management Candidate

    The FDA has set an action date of Mar 24, 2019 for Recro's lead product candidate, intravenous (IV) meloxicam, for the management of moderate to severe pain.

  • Take two: Recro tries for second time to get FDA approval for its non-opioid pain medicine
    American City Business Journals9 days ago

    Take two: Recro tries for second time to get FDA approval for its non-opioid pain medicine

    The FDA expects to make a decision by late March on Recro Pharma's resubmitted new drug application for intravenous meloxicam.

  • GlobeNewswire10 days ago

    Recro Pharma Announces PDUFA Date for IV Meloxicam

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that the U.S. Food and Drug Administration (FDA) has set a PDUFA goal date of March 24, 2019 for its decision on the New Drug Application (NDA) for intravenous (IV) meloxicam for the management of moderate to severe pain. Recro resubmitted the NDA for IV meloxicam in September 2018 in reply to a Complete Response Letter (CRL) received from the U.S. FDA in May 2018.

  • GlobeNewswire17 days ago

    Recro Announces Expansion of CDMO Service Capabilities

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced the opening of an expanded 24,000 square foot GMP development and high potency product services facility in Gainesville, GA. The new site, which is near the existing 97,000 square foot, DEA-licensed CDMO facility, houses an expanded development space focused on creating unique oral dosage forms, solving formulation, process and analytical issues, as well as providing additional capacity for clinical trial supply manufacturing and related services. In addition, the expanded facility has specialized space dedicated to the development and GMP manufacturing of high potency products.  The new development facility is currently operational, and the high potency GMP suite will be operational shortly.

  • GlobeNewswirelast month

    Recro Pharma to Participate in Upcoming Investor Conferences

    Recro Pharma is a specialty pharmaceutical company that operates through two business divisions, an Acute Care, hospital product division and a revenue-generating contract development and manufacturing, or CDMO division, located in Gainesville, GA. The Acute Care division is primarily focused on developing innovative products for hospital and other acute care settings.

  • GlobeNewswirelast month

    Recro Pharma to Present IV Meloxicam Data at PAINWeek® 2018

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced three poster presentations at PAINWeek 2018, taking place September 4-8, 2018, in Las Vegas, NV.  The poster presentations highlight key clinical efficacy and safety data relating to the Company’s lead product candidate intravenous (IV) meloxicam, which is currently in development for the treatment of moderate to severe pain.

  • ACCESSWIRElast month

    3 Stocks to Watch As The Healthcare Sector Heats Up

    CORAL GABLES, FL / ACCESSWIRE / September 4, 2018 / Health care stocks have made a sharp swing to the upside so far in the third quarter, leading the some of the major markets like the S&P 500. "Overall they look quite good," stated Matt Maley, equity strategist at Miller Tabak, in an interview with CNBC. Thehealth care ETF (XLV), he adds, has "been making a nice series of higher highs and higher lows." During this same period, a number of bigger companies are using their large cash positions to targetsmall cap biotech companies through strategic investments and setting sights on new acquisitions.

  • GlobeNewswirelast month

    Recro Pharma Provides Regulatory Update for IV Meloxicam

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today provided a regulatory update following receipt of the official meeting minutes from a July 2018 Type A meeting with the U.S. Food and Drug Administration (FDA) relating to a path forward for intravenous (IV) meloxicam, the Company’s lead product candidate for the management of moderate to severe pain. Recro had requested this Type A meeting with the FDA to address a Complete Response Letter (CRL) it received from the FDA regarding the New Drug Application (NDA) for IV meloxicam.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of REPH earnings conference call or presentation 7-Aug-18 12:00pm GMT

    Q2 2018 Recro Pharma Inc Earnings Call

  • Recro Pharma (REPH) Reports Q2 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Recro Pharma (REPH) Reports Q2 Loss, Tops Revenue Estimates

    Recro Pharma (REPH) delivered earnings and revenue surprises of 54.07% and 29.35%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Recro Pharma: 2Q Earnings Snapshot

    The Malvern, Pennsylvania-based company said it had a loss of 62 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    Recro Pharma Reports Second Quarter 2018 Financial Results

    MALVERN, Pa., Aug. 07, 2018-- Recro Pharma, Inc., a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today reported financial ...

  • ACCESSWIRE2 months ago

    Recro Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Recro Pharma, Inc. (NASDAQ: REPH ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:00 AM Eastern Time. ...

  • Benzinga2 months ago

    Recro Pharma Q2 Earnings Preview

    On Tuesday, Recro Pharma (NASDAQ: REPH ) will report its last quarter's earnings. Here is Benzinga's take on the company's release. Earnings and Revenue Analysts are expecting Recro Pharma to report a ...

  • GlobeNewswire3 months ago

    Recro Pharma to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018

    Recro Pharma, Inc. (REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, today announced that it will report second quarter financial results on Tuesday, August 7, 2018. Recro's management team will host a conference call and audio webcast at 8:00 a.m. ET on Tuesday, August 7, 2018 to discuss the financial results and recent operational highlights. A live audio webcast of the call will be available under "Events" in the Investor section of the Company's website, https://ir.recropharma.com/events.

  • GlobeNewswire3 months ago

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TAL, QCOM, REVG, FLKS and REPH

    NEW YORK, July 30, 2018-- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...

  • ACCESSWIRE3 months ago

    FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $50K of Class Action Against Recro Pharma, Inc. (REPH) & Lead Plaintiff Deadline: July 30, 2018

    NEW YORK, NY / ACCESSWIRE / July 30, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Recro Pharma, Inc. ("Recro" or the "Company") ...

  • GlobeNewswire3 months ago

    SHAREHOLDER ALERT: TAL ORA REVG FPI NWL PCG REPH: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, July 29, 2018-- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...

  • GlobeNewswire3 months ago

    Glancy Prongay & Murray LLP Reminds Investors of Lead Plaintiff Deadline in the Class Action Lawsuit Against Recro Pharma, Inc. (REPH)

    Glancy Prongay & Murray LLP (“GPM”) reminds investors of the July 30, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Recro Pharma, Inc. (“Recro Pharma” or the “Company”) (NASDAQ: REPH) securities between July 31, 2017, and May 23, 2018, inclusive (the “Class Period”). The complaint filed in this class action alleges that, Recro Pharma made false and misleading statements to the marketplace, and that the Company’s lead product, IV meloxicam, was unlikely to receive FDA approval because it lacked sufficient supporting clinical data to demonstrate significant clinical benefits.

  • GlobeNewswire3 months ago

    CLASS ACTION UPDATE for ORA and REPH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, July 27, 2018-- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving ...

  • ACCESSWIRE3 months ago

    3-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Recro Pharma, Inc. and Reminds Investors with Losses to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / July 27, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Recro Pharma, Inc. (''Recro Pharma" or ''the Company'') (NASDAQ: REPH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between July 31, 2017, and May 23, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before July 30, 2018.

  • ACCESSWIRE3 months ago

    DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $50K of Class Action Against Recro Pharma, Inc. (REPH) & Lead Plaintiff Deadline: July 30, 2018

    NEW YORK, NY / ACCESSWIRE / July 27, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Recro Pharma, Inc. ("Recro" or the "Company") ...

  • GlobeNewswire3 months ago

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MRCY, REVG and REPH

    NEW YORK, July 26, 2018-- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead ...

  • Business Wire3 months ago

    MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Recro Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Recro Pharma, Inc. (“Recro Pharma” or “the Company”) (NASDAQ: REPH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between July 31, 2017, and May 23, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before July 30, 2018.